The present invention provides a compound having the structure:

##STR00001##

wherein
X.sub.1 is N or CR.sub.5, wherein R.sub.5 is H, OH, halogen or alkyl;
X.sub.2, X.sub.3 and X.sub.4 are each independently NH, N, S, O or CR.sub.6, wherein each R.sub.6 is independently H, OH, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, haloalkyl, O(alkyl), S(alkyl), NH.sub.2, NH(alkyl), N(alkyl).sub.2 or CO.sub.2H;
R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each independently H, F, Cl, Br, I, NO.sub.2, CN, CF.sub.3, CF.sub.2H, OCF.sub.3, -(alkyl), -(haloalkyl), -(alkenyl), -(alkynyl), -(aryl), -(heteroaryl), -(cycloalkyl), -(cycloalkylalkyl), -(heteroalkyl), heterocycle, heterocycloalkyl, -(alkylheteroalkyl), -(alkylaryl), OH, OAc, O-(alkyl), O-(alkenyl), O-(alkynyl), O-(aryl), (heteroaryl), SH, S-(alkyl), S-(alkenyl), S-(alkynyl), S-(aryl), S-(heteroaryl), NH.sub.2, NH-(alkyl), NH-(alkenyl), NH-(alkynyl), NH-(aryl), NH-(heteroaryl), C(O)R.sub.7, S(O)R.sub.7, SO.sub.2R.sub.7, NHSO.sub.2R.sub.7, OC(O)R.sub.7, SC(O)R.sub.7, NHC(O)R.sub.7 or NHC(S)R.sub.7,
wherein R.sub.7 is, H, (alkyl), OH, O(alkyl), NH.sub.2, NH(alkyl) or N(alkyl).sub.2;
B is absent or present, and when present is

##STR00002## wherein R.sub.8 is H, OH, halogen, alkyl, cycloalkyl, cycloalkylalkyl, O-(alkyl), S-(alkyl), NH.sub.2, NH-(alkyl), N(alkyl).sub.2 or CO.sub.2H; and
C is H, substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, aryl, heteroaryl, alkyl, cycloalkyl, cycloalkylalkyl, CO.sub.2H, COOR.sub.9, OH, OR.sub.9, NH.sub.2, NHR.sub.9, NR.sub.9R.sub.10, SO.sub.2R.sub.11, CH.sub.2NHR.sub.9, CH.sub.2NR.sub.9R.sub.10 or CH.sub.2COOR.sub.9, wherein R.sub.9 and R.sub.10 are each independently H, alkyl, cycloalkyl, C(O)-alkyl, C(O)-cycloalkyl, C(O)OH, C(O)O-alkyl, C(O)O-cycloalkyl, C(O)NH.sub.2, C(O)NH(alkyl), C(O)NH(cycloalkyl), C(O)N(alkyl).sub.2, CH.sub.2NH(alkyl), CH.sub.2COOH, SO.sub.2CH.sub.3, OH, O(alkyl), NH.sub.2, NH(alkyl) or N(alkyl) wherein R.sub.11 is alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, NH.sub.2, NH(alkyl), NH(cycloalkyl), NH(heterocycle), NH(aryl), NH(heteroaryl) or NHCOR.sub.12, wherein R.sub.12 is alkyl, haloalkyl, cycloalkyl, heterocycle, aryl or heteroaryl,
or a pharmaceutically acceptable salt thereof.

The present invention provides compounds useful for treating or preventing a brain-related disease or disorder. The present invention further provides a method of treating or preventing a brain-related disease or disorder in a patient, comprising administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of modulating the activity of a monoamine transporter.

The present invention provides compounds useful for treating or preventing a brain-related disease or disorder. The present invention further provides a method of treating or preventing a brain-related disease or disorder in a patient, comprising administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of modulating the activity of a monoamine transporter.

The present invention provides methods, compositions, mixtures and kits utilizing 5-Chloro-2-methyl-4-isothiazolin-3-one in sequencing reactions, and in particular, sequencing reactions where deoxynucleoside triphosphates comprising a 3-O position capped by a disulfide-based 3-terminator group are used. In one embodiment, the deoxynucleoside triphosphates comprise a 3-O position capped by a group comprising methylenedisulfide as a cleavable protecting group and a detectable label reversibly connected to the nucleobase of said deoxynucleoside. In addition, thiol-containing compounds and scavengers of thio-containing compounds are described. Such compounds provide new possibilities for future sequencing technologies, including but not limited to Sequencing by Synthesis.

This disclosure relates to a composition comprising (a) 4,4-methylene diphenyl diisocyanate (4,4-MDI), and (b) at least one heterocyclic compound comprising as ring moiety at least one structure of formula (I) as defined in the description. The heterocyclic compound can suppress the formation of 4,4-MDI dimer and thus prevent the formation of insoluble solids and extend the shelf life of 4,4-MDI.

This disclosure relates to a composition comprising (a) 4,4-methylene diphenyl diisocyanate (4,4-MDI), and (b) at least one heterocyclic compound comprising as ring moiety at least one structure of formula (I) as defined in the description. The heterocyclic compound can suppress the formation of 4,4-MDI dimer and thus prevent the formation of insoluble solids and extend the shelf life of 4,4-MDI.

Compositions of the invention comprise 1,2-dithiolane, dithiol and related compounds useful as therapeutic agents for the treatment and prevention of diseases and conditions associated with aberrant EGFR activity.

Compositions of the invention comprise 1,2-dithiolane, dithiol and related compounds useful as therapeutic agents for the treatment and prevention of diseases and conditions associated with aberrant EGFR activity.

The invention relates to compounds acting as agonists of G-protein coupled receptor 120 (GPR120) and/or 40 (GPR40), and having formula (I):

##STR00001##

Said compounds are useful in the treatment of diseases or disorders modulated by GPR120 and/or GPR40 such as diabetes (particularly type 2 diabetes), impaired oral glucose tolerance, insulin resistance, obesity, obesity related disorders, metabolic syndrome, dyslipidemia, elevated LDL, elevated triglycerides, obesity induced inflammation, osteoporosis and obesity related cardiovascular disorders.

The invention relates to compounds acting as agonists of G-protein coupled receptor 120 (GPR120) and/or 40 (GPR40), and having formula (I):

##STR00001##

Said compounds are useful in the treatment of diseases or disorders modulated by GPR120 and/or GPR40 such as diabetes (particularly type 2 diabetes), impaired oral glucose tolerance, insulin resistance, obesity, obesity related disorders, metabolic syndrome, dyslipidemia, elevated LDL, elevated triglycerides, obesity induced inflammation, osteoporosis and obesity related cardiovascular disorders.